About Replicate Bioscience
Replicate Bioscience is a company based in San Diego (United States) founded in 2019 by Nathaniel Wang and Andy Geall.. Replicate Bioscience has raised $46 million across 2 funding rounds from investors including Apple Tree Partners. The company has 8 employees as of December 31, 2021. Replicate Bioscience offers products and services including srRNA Platform and srRNA Rabies Vaccine. Replicate Bioscience operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter San Diego, United States
- Employees 8 as on 31 Dec, 2021
- Founders Nathaniel Wang, Andy Geall
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Replicate Bioscience, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$46 M (USD)
in 2 rounds
-
Latest Funding Round
$40 M (USD), Series A
Sep 08, 2021
- Investors
-
Employee Count
8
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Replicate Bioscience
Replicate Bioscience offers a comprehensive portfolio of products and services, including srRNA Platform and srRNA Rabies Vaccine. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables self-replicating RNA for enhanced protein expression in treatments.
Optimized RNA-based vaccine for rabies prevention and immunogenicity.
Unlock access to complete
Unlock access to complete
Leadership Team
4 people
Advisor Team
2 people
Product Management Team
2 people
Founder Team
1 people
Unlock access to complete
Funding Insights of Replicate Bioscience
Replicate Bioscience has successfully raised a total of $46M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $40 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $40.0M
-
First Round
First Round
(16 Feb 2021)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2021 | Amount | Series A - Replicate Bioscience | Valuation |
investors |
|
| Feb, 2021 | Amount | Series A - Replicate Bioscience | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Replicate Bioscience
Replicate Bioscience has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Apple Tree Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Apple Tree Partners is engaged in life sciences venture capital.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Replicate Bioscience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Replicate Bioscience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Replicate Bioscience Comparisons
Competitors of Replicate Bioscience
Replicate Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Replicate Bioscience
Frequently Asked Questions about Replicate Bioscience
When was Replicate Bioscience founded?
Replicate Bioscience was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Replicate Bioscience located?
Replicate Bioscience is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Replicate Bioscience?
Nathaniel Wang is the current CEO of Replicate Bioscience. They have also founded this company.
Is Replicate Bioscience a funded company?
Replicate Bioscience is a funded company, having raised a total of $46M across 2 funding rounds to date. The company's 1st funding round was a Series A of $6M, raised on Feb 16, 2021.
How many employees does Replicate Bioscience have?
As of Dec 31, 2021, the latest employee count at Replicate Bioscience is 8.
What does Replicate Bioscience do?
Replicate Bioscience was founded in 2019 and is headquartered in San Diego, United States. Operations focus on the biotechnology sector, specifically the development of RNA-based drug delivery systems for cancer treatment. Self-replicating RNA platforms have been created to enable the immune system to identify and destroy cancerous cells. Immuno-oncology approaches and targeted therapies are also being advanced to address various cancer types.
Who are the top competitors of Replicate Bioscience?
Replicate Bioscience's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
What products or services does Replicate Bioscience offer?
Replicate Bioscience offers srRNA Platform and srRNA Rabies Vaccine.
Who are Replicate Bioscience's investors?
Replicate Bioscience has 1 investor. Key investors include Apple Tree Partners.